We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Assayed Liquid Immunoassay Control Made Available

By LabMedica International staff writers
Posted on 16 Apr 2012
The Acusera Liquid Immunoassay Control is designed to be both easy and convenient to use and eliminates the need for reconstitution thus reducing the amount of human handling necessary and the subsequent risk of pipetting errors. More...


The recent inclusion of fully assayed target values and ranges for over 40 analytes enables laboratories to reduce the number of controls used and ultimately reduce costs and accurately assigned assayed target values are even provided for most immunoassay analyzers.

The combination of routine immunoassay analytes and a wide range of therapeutic drugs in a single liquid control material allows for increased efficiency across several areas of the clinical laboratory. As a true third party control, an unbiased, independent assessment of performance is guaranteed. Third Party is the term used to describe a control that has not been designed or optimized for use with a specific test or system. As such, they mirror the performance of patient samples and provide an unbiased, independent assessment of analytical performance.

The material is 100% human in origin providing a matrix similar to the patient sample but also reducing antibody interference and the possibility of control values shifting after changing reagent batch. Three clinically significant levels of control are available, supplied either separately or in a convenient and cost effective tri-level pack. A 5 mL vial size and open vial stability of seven days at 2-8 °C minimizes waste and helps to keep costs low.

The Acusera Liquid Immunoassay Control (Randox Laboratories Ltd; Crumlin, UK) is compatible for use with Acusera 24.7, a web based interlaboratory data management program. Users of Acusera 24.7 benefit from optimum performance and gain access to peer group data from laboratories worldwide. Peer group data is uniquely updated every 24 hours giving access to the most up to date information available.

Related Links:

Randox Laboratories Ltd.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.